Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care System
ABSTRACT Differential diagnosis of COVID-19 and/or influenza (flu) at point of care is critical for efficient patient management and treatment of both these diseases. The study presented here characterizes the BD Veritor System for Rapid Detection of SARS-CoV-2 and Flu A+B (“Veritor SARS-CoV-2/Flu”)...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2022-04-01
|
| Series: | Microbiology Spectrum |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/spectrum.01807-21 |
| _version_ | 1811303423286444032 |
|---|---|
| author | Katherine Christensen Huimiao Ren Shirley Chen Charles K. Cooper Stephen Young |
| author_facet | Katherine Christensen Huimiao Ren Shirley Chen Charles K. Cooper Stephen Young |
| author_sort | Katherine Christensen |
| collection | DOAJ |
| description | ABSTRACT Differential diagnosis of COVID-19 and/or influenza (flu) at point of care is critical for efficient patient management and treatment of both these diseases. The study presented here characterizes the BD Veritor System for Rapid Detection of SARS-CoV-2 and Flu A+B (“Veritor SARS-CoV-2/Flu”) triplex assay. The performance for SARS-CoV-2 detection was determined using 298 specimens from patients reporting COVID-19 symptoms within 7 days from symptom onset (DSO) in comparison with the Lyra SARS-CoV-2 RT-PCR (reverse transcriptase PCR) assay (“Lyra SARS-CoV-2”) as the reference. The performance for flu A and flu B detection was determined using 75 influenza-positive and 40 influenza-negative retrospective specimens in comparison with the previously FDA-cleared BD Veritor System for Rapid Detection of Flu A+B assay (“Veritor Flu”) as the reference. The Veritor SARS-CoV-2/Flu assay met the FDA EUA acceptance criteria (86.7%; 95% confidence interval [95% CI]: 75.8 to 93.1) for SARS-CoV-2 testing compared to Lyra SARS-CoV-2. The Veritor SARS-CoV-2/Flu assay also demonstrated 100% agreement with the Veritor Flu for Flu A+B assay. For flu A detection, the lower bound of the 95% CI was 91.2%; for flu B detection, the lower bound was 90.0%. The dual detection capability of Veritor SARS-CoV-2/Flu for the etiologic agents causing COVID-19 and flu will allow efficient differentiation between the two illnesses, inform disease management, and facilitate optimal treatment. IMPORTANCE COVID-19 and flu are two respiratory illnesses which share similar clinical symptoms. The BD Veritor SARS-CoV-2/Flu assay has high sensitivity and specificity for detecting the SARS-CoV-2 and influenza A/B, the two etiologic agents causing COVID-19 and flu, respectively. This dual detection capability is critical when overlap occurs between the COVID-19 pandemic and the flu season. This triplex assay will allow efficient differentiation between the two respiratory illnesses and support a point-of-care physician diagnosis to facilitate the proper treatment and disease management for patients exhibiting overlapping symptoms. |
| first_indexed | 2024-04-13T07:47:44Z |
| format | Article |
| id | doaj.art-32386313555c403c841cdedd07add4d1 |
| institution | Directory Open Access Journal |
| issn | 2165-0497 |
| language | English |
| last_indexed | 2024-04-13T07:47:44Z |
| publishDate | 2022-04-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | Microbiology Spectrum |
| spelling | doaj.art-32386313555c403c841cdedd07add4d12022-12-22T02:55:38ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972022-04-0110210.1128/spectrum.01807-21Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care SystemKatherine Christensen0Huimiao Ren1Shirley Chen2Charles K. Cooper3Stephen Young4Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, Maryland, USABecton, Dickinson and Company, BD Life Sciences, San Diego, California, USABecton, Dickinson and Company, BD Life Sciences, San Diego, California, USABecton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, Maryland, USATricore Reference Laboratory, Albuquerque, New Mexico, USAABSTRACT Differential diagnosis of COVID-19 and/or influenza (flu) at point of care is critical for efficient patient management and treatment of both these diseases. The study presented here characterizes the BD Veritor System for Rapid Detection of SARS-CoV-2 and Flu A+B (“Veritor SARS-CoV-2/Flu”) triplex assay. The performance for SARS-CoV-2 detection was determined using 298 specimens from patients reporting COVID-19 symptoms within 7 days from symptom onset (DSO) in comparison with the Lyra SARS-CoV-2 RT-PCR (reverse transcriptase PCR) assay (“Lyra SARS-CoV-2”) as the reference. The performance for flu A and flu B detection was determined using 75 influenza-positive and 40 influenza-negative retrospective specimens in comparison with the previously FDA-cleared BD Veritor System for Rapid Detection of Flu A+B assay (“Veritor Flu”) as the reference. The Veritor SARS-CoV-2/Flu assay met the FDA EUA acceptance criteria (86.7%; 95% confidence interval [95% CI]: 75.8 to 93.1) for SARS-CoV-2 testing compared to Lyra SARS-CoV-2. The Veritor SARS-CoV-2/Flu assay also demonstrated 100% agreement with the Veritor Flu for Flu A+B assay. For flu A detection, the lower bound of the 95% CI was 91.2%; for flu B detection, the lower bound was 90.0%. The dual detection capability of Veritor SARS-CoV-2/Flu for the etiologic agents causing COVID-19 and flu will allow efficient differentiation between the two illnesses, inform disease management, and facilitate optimal treatment. IMPORTANCE COVID-19 and flu are two respiratory illnesses which share similar clinical symptoms. The BD Veritor SARS-CoV-2/Flu assay has high sensitivity and specificity for detecting the SARS-CoV-2 and influenza A/B, the two etiologic agents causing COVID-19 and flu, respectively. This dual detection capability is critical when overlap occurs between the COVID-19 pandemic and the flu season. This triplex assay will allow efficient differentiation between the two respiratory illnesses and support a point-of-care physician diagnosis to facilitate the proper treatment and disease management for patients exhibiting overlapping symptoms.https://journals.asm.org/doi/10.1128/spectrum.01807-21BD VeritorCOVID-19SARS-CoV-2influenzaflutriplex antigen assay |
| spellingShingle | Katherine Christensen Huimiao Ren Shirley Chen Charles K. Cooper Stephen Young Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care System Microbiology Spectrum BD Veritor COVID-19 SARS-CoV-2 influenza flu triplex antigen assay |
| title | Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care System |
| title_full | Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care System |
| title_fullStr | Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care System |
| title_full_unstemmed | Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care System |
| title_short | Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care System |
| title_sort | clinical evaluation of bd veritor sars cov 2 and flu a b assay for point of care system |
| topic | BD Veritor COVID-19 SARS-CoV-2 influenza flu triplex antigen assay |
| url | https://journals.asm.org/doi/10.1128/spectrum.01807-21 |
| work_keys_str_mv | AT katherinechristensen clinicalevaluationofbdveritorsarscov2andfluabassayforpointofcaresystem AT huimiaoren clinicalevaluationofbdveritorsarscov2andfluabassayforpointofcaresystem AT shirleychen clinicalevaluationofbdveritorsarscov2andfluabassayforpointofcaresystem AT charleskcooper clinicalevaluationofbdveritorsarscov2andfluabassayforpointofcaresystem AT stephenyoung clinicalevaluationofbdveritorsarscov2andfluabassayforpointofcaresystem |